<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49128">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466659</url>
  </required_header>
  <id_info>
    <org_study_id>IndianU</org_study_id>
    <nct_id>NCT02466659</nct_id>
  </id_info>
  <brief_title>Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia</brief_title>
  <acronym>CIAO</acronym>
  <official_title>A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness of alternate occlusion therapy for the treatment of IXT among
      patients aged 3 to &lt; 11 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent exotropia (IXT) is the most common form of childhood-onset exotropia with an
      incidence of 32.1 per 100,000 in children. Before surgery, many cases of IXT are treated
      using non-surgical interventions, such as part-time alternate occlusion. However, the
      &quot;alternating&quot; occlusion with traditional patches is usually out of control. The
      investigators are uncertain about the amount of &quot;alternating&quot; in patching treatment.

      Here, the investigators introduce controlled intermittent alternating occlusion (CIAO)
      therapy, which is provided by a new electronic device, -liquid crystal glasses. This study
      is to determine the effectiveness of alternate occlusion therapy for the treatment of IXT
      among patients aged 3 to &lt; 11 years old. Children with IXT will be randomized into either an
      observation group or a CIAO therapy group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Composite measure of IXT control score and IXT deviation</measure>
    <time_frame>12 weeks; 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Intermittent Exotropia</condition>
  <arm_group>
    <arm_group_label>CIAO Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with wearing 3-hour daily CIAO therapy glasses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To observe as one kind of standard care for IXT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CIAO therapy Amblyz glasses</intervention_name>
    <description>3-hour CIAO Therapy Amblyz glasses</description>
    <arm_group_label>CIAO Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermittent exotropia (manifest deviation) meeting all of the following criteria:

               -  Intermittent exotropia at distance OR constant exotropia at distance and either
                  intermittent exotropia or exophoria at near

               -  Exodeviation at least 15PD at distance OR near measured by prism and alternate
                  cover test (PACT)

               -  Exodeviation at least 10PD at distance measured by PACT

          -  No previous surgical or non-surgical treatment for IXT (other than refractive
             correction)

          -  Visual acuity in the worse eye 0.3 logMAR or better (20/40 on ATS HOTV or 70 letters
             on E-ETDRS) for children ≥ 3 years of age

          -  No interocular difference of visual acuity more than 0.2 logMAR (2 lines on ATS HOTV
             or 10 letters on E-ETDRS) for children ≥ 7 years of age

          -  Investigator not planning to initiate amblyopia treatment

          -  No hyperopia greater than +3.50 D spherical equivalent in either eye

          -  No myopia greater than -6.00 D spherical equivalent in either eye

          -  No prior strabismus, intraocular, or refractive surgery

          -  No abnormality of the cornea, lens, or central retina

          -  Investigator willing to observe the IXT untreated for 3 years unless specific
             criteria for deterioration are met.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel E Neely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glick Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingyun Wang, PhD</last_name>
    <phone>3179481403</phone>
    <email>jinwang@iupui.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glick Eye Institute, Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingyun Wang, PhD</last_name>
      <phone>317-948-1403</phone>
      <email>jinwang@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michele Whitaker</last_name>
      <phone>3179448103</phone>
      <email>mewhitak@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jingyun Wang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>April 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Daniel E. Neely</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>IXT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exotropia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
